image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Filing date Description Form View

Statement of changes in beneficial ownership of securities

4 View HTML

Statement of changes in beneficial ownership of securities

4 View HTML

Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

DRS View HTML

A statement of beneficial ownership of common stock by certain persons

SC 13G View HTML

An amendment to the SC 13G filing

SC 13G/A View HTML

Report of unscheduled material events or corporate event

8-K View HTML

Annual report which provides a comprehensive overview of the company for the past year

10-K EX-101.INS - XBRL INSTANCE DOCUMENT View HTML

A statement of beneficial ownership of common stock by certain persons

SC 13G View HTML

A statement of beneficial ownership of common stock by certain persons

SC 13G View HTML

Securities offered to employees pursuant to employee benefit plans

S-8 View HTML

Data provided by Kaleidoscope.